Manufacturer
Pharmaniaga Manufacturing Berhad
Primary hypercholesterolemia (Type IIa, including familial heterozygous)
Mixed dyslipidemia (Type IIb), primary dysbetalipoproteinemia (Type III), and homozygous familial hypercholesterolemia (HoFH)
To reduce cardiovascular risk in patients with high risk of heart events (e.g. stroke or heart attack)
Initial adult dose: 10 /mg once daily, taken with or without food.
Some patients (especially Asian populations or those at risk for muscle toxicity) may start at 5 /mg daily.
Dosage may be increased up to a maximum of 20 /mg daily if LDL-C targets are not reached after 4 weeks.
Liver function tests and creatine kinase (CK) monitoring are recommended during use. Contraindicated in active liver disease, pregnancy, breastfeeding, or hypersensitivity to rosuvastatin
Malaysia
